Conférences
le (58m17s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 131
Label UNT Conférences
le (15m37s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
... syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to more swiftly and reliably establish/reject a diagnosis, to more accurately estimate prognosis, or to inform more successful... Voir la vidéo
Label UNT Conférences
le (4m2s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
... a biomarker provides independently useful information involved in the diagnosis, prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to... Voir la vidéo
Label UNT Conférences
le (14m51s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
... prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to more swiftly and reliably establish/reject a diagnosis, to more accurately estimate... Voir la vidéo
Label UNT Conférences
le (10m1s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
... diagnosis, prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to more swiftly and reliably establish/reject a diagnosis, to more accurately... Voir la vidéo
Label UNT Conférences
le (7m59s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
... prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to more swiftly and reliably establish/reject a diagnosis, to more accurately estimate... Voir la vidéo
Conférences
le (1h6m55s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)
... in high risk patients when treatment targets based on new ESC guidelines have been achieved (e.g. LDL-C < 70mg/dl)?Despite widespread early intervention in acute coronary syndromes and complete revascularization of stenotic lesions complemented by... Voir la vidéo
Label UNT Conférences
le (17m30s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
... information involved in the diagnosis, prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to more swiftly and reliably establish/reject a... Voir la vidéo
Label UNT Conférences
le (3m24s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
... a biomarker provides independently useful information involved in the diagnosis, prognosis, progression or therapy of HF syndromes.4. The biomarker must provide clinically useful information for caregivers (physician, nurses, patient and others) to... Voir la vidéo
Label UNT Conférences
le (20m35s)
